Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

CompuGroup Medical: Strong second quarter with 10á%áorganic growth

08/05/2021 | 01:56am EST
  • Group revenues grow significantly by 34 % in the second quarter, thereof 10% organic growth
  • Adjusted EBITDA grows by 14 %, operating margin of 21 %
  • Numerous solutions across Europe support doctors and medical staff in vaccination
  • Strong performance of hospital business with 15 % organic growth
  • Approval of next generation connector upgrade and continued successful Telematics Infrastructure (TI) rollout
  • Full-year 2021 guidance confirmed

CompuGroup Medical SE & Co. KGaA (CGM), one of the leading e-health providers in the world, is reporting a strong second quarter. The quarterly results published today prove the growing demand for digital solutions in healthcare for various markets, as highlighted by the ongoing pandemic. Accordingly, CGM recorded significant organic growth in the second quarter of 2021, driven - among others - by a strong organic revenue growth in the Hospital Information Systems (HIS) and Consumer and Health Management Information Systems (CHS) segments.

Dr. Dirk Wössner Chief Executive Officer (CEO)

'The goal of our investment initiative that we started in the beginning of 2021 is to accelerate organic growth. The second quarter is a very good milestone towards this goal with an excellent organic growth of 10 %,' said Dr. Dirk Wössner, CEO of CompuGroup Medical. 'We achieved an impressive performance in the hospital business, and we also see accelerating growth in our Ambulatory Information Systems segment, mostly driven by a strong European business. In addition, the rollout of modules supporting the electronic health record in Germany is contributing to this. We expect this trend to continue and accelerate in the second half of 2021.'

Michael Rauch, CFO of CompuGroup Medical, added, 'Free cashflow for the first half year of 2021 grew significantly by 35 % compared to the previous year. Also, the accelerated organic growth and a further increase of EBITDA margin throughout the year demonstrate that we are on the right track. We are confirming our full year guidance.'

Group: Well on track with organic growth picking up

CGM recorded a strong second quarter with group revenues increasing by 34 % to EUR 241 million. Organically - i.e. adjusted for consolidation and currency effects - they rose by 10 %. Adjusted EBITDA increased by 14 % to EUR 51 million (previous year: EUR 45 million). The operating margin is 21 % after 25 % in the previous year due to the announced investments into further growth. Recurring revenues now amount to 67 % of total revenues within the Group, compared to 69 % in the second quarter of 2020.

Michael Rauch, Chief Financial Officer (CFO)

In the first half of 2021, free cashflow reached EUR 65 million (previous year: EUR 48 million) - an increase of 35 % compared to the previous year. Free cashflow in Q2 was EUR -5.8 million (previous year: EUR -3.2 million) as expected. Consolidated net income in the second quarter was EUR 17 million (previous year: EUR 16 million). Adjusted earnings per share (diluted) amounted to EUR 0.43 (previous year: EUR 0.38).

CGM confirms its guidance for the full year. For 2021, revenues in the range of EUR 1 billion to EUR 1.04 billion are expected. The adjusted EBITDA for 2021 is expected to be between EUR 210 million and EUR 230 million.

Segments: Strong development across the CGM business

Revenues in the Ambulatory Information Systems segment benefit from the well-performing eMDs merger in the US and increased by 24 % to EUR 115 million (previous year: EUR 93 million). Organically, revenues rose by 3 % to EUR 95 million driven by a strong performance of the European business. Recurring revenues amounted to 76 % of total revenues (previous year: 76 %). With EUR 29 million, adjusted EBITDA was slightly below the previous year (EUR 31 million). CGM supported its customers with numerous solutions for vaccination management. After launching a freemium offer for vaccination management with the module ImpfdocNE, CGM successfully participated in a tender of the German Ministry of Health to roll out an add-on tool to create vaccination certificates in doctors' software. In addition, the AIS segment successfully launched software packages to enable handling electronic health records in doctors' offices.

The Hospital Information Systems segment showed a revenue growth of 86 % to EUR 62 million (previous year: EUR 33 million), while adjusted EBITDA grew by 145 % to EUR 13 million (previous year: EUR 5.4 million). The excellent organic revenue growth of 15 % is attributable to a strong performance in Germany, Poland and the Laboratory Information Systems business. Further growth effects are expected to result from a high number of leads related to the Hospital Future Act in Germany and from major orders including Kantonsspital Graubünden in Switzerland and the Murcia region in Spain with ten participating hospitals. In June, CGM strengthened its profile in the HIS business with the acquisition of VISUS Health IT, one of the leading providers for Picture Archiving and Communication Systems (PACS) and Healthcare Content Management.

The Consumer & Health Management Information Systems segment increased revenues by 41 % to EUR 36 million (previous year: EUR 25 million). Organic revenues grew by an impressive 42 % to EUR 36 million (previous year: EUR 25 million). This development was significantly driven by Telematics Infrastructure with strong card reader sales and the continued rollout to pharmacies in Germany. After the approval from gematik for the nationwide rollout of CGM's KoCoBox MED+ as a connector for the electronic health record, further revenue growth is expected for the second half of 2021. Excluding TI growth, the organic revenue increase was 10 %, mostly driven by a strong performance in data solutions. Adjusted EBITDA amounted to EUR 5.7 million and 31 % above the previous year's figure (EUR 4.4 million).

The Pharmacy Information Systems segment recorded an adjusted EBITDA growth by 12 % to EUR 8.4 million (previous year: EUR 7.5 million) in the second quarter of 2021 with an operating margin of 29 % (previous year: 26 %). Both are based on revenues of EUR 28 million, slightly below the previous year (EUR 29 million). The share of recurring revenues increased from 66 % to 69 %.

The full quarterly report is available at IR Publications.


CompuGroup Medical SE published this content on 05 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 August 2021 05:55:03 UTC.

ę Publicnow 2021
11/25CompuGroup Medical To Launch $42 Million Share Buyback
11/25COMPUGROUP MEDICAL SE & CO. KGAA : Release of a capital market information
11/25CompuGroup Medical SE & Co. KGaA adopts resolution on share buy-back program for up to ..
11/11COMPUGROUP MEDICAL : Gets a Buy rating from Berenberg
11/09COMPUGROUP MEDICAL : Baader Bank remains a Sell rating
11/08COMPUGROUP MEDICAL : Kepler Cheuvreux gives a Neutral rating
11/04CompuGroup Medical SE & Co. KGaA Reports Earnings Results for the Third Quarter and Nin..
11/04COMPUGROUP MEDICAL : Kepler Cheuvreux remains Neutral
11/04COMPUGROUP MEDICAL : Gets a Buy rating from Warburg Research
11/04COMPUGROUP MEDICAL : Baader Bank reaffirms its Sell rating
More news
Analyst Recommendations on COMPUGROUP MEDICAL SE & CO. KGAA
More recommendations
Sales 2021 1 022 M 1 155 M 1 155 M
Net income 2021 80,6 M 91,1 M 91,1 M
Net Debt 2021 512 M 578 M 578 M
P/E ratio 2021 44,3x
Yield 2021 0,85%
Capitalization 3 520 M 3 981 M 3 976 M
EV / Sales 2021 3,94x
EV / Sales 2022 3,66x
Nbr of Employees 8 079
Free-Float 48,8%
Duration : Period :
CompuGroup Medical SE & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGROUP MEDICAL SE & CO. KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 10
Last Close Price 66,75 €
Average target price 84,80 €
Spread / Average Target 27,0%
EPS Revisions
Managers and Directors
Dirk W÷ssner Chairman-Management Board & CEO
Philipp von Ilberg Chairman-Supervisory Board
Frank Brecher Chief Technology Officer
Sven Thomas MŘller Vice Chairman & Chief Information Officer
Ulrike Handel Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
SAP SE6.44%152 226
SERVICENOW, INC.13.25%124 048
DOCUSIGN, INC.5.18%45 997
HUBSPOT, INC.93.13%37 503